Table 6.

Details of recurrent and new irAEs out of 14 patients with readministered ICI after irAE occurrence.

Case	IrAEs that caused first interruption of ICI	CTCAE grade	IrAEs with readministration	CTCAE grade	ICI continuation	ICI after readministration
1	Pneumonitis	1	Pneumonitis	1	Continued	NA
2	Thyroid dysfunction	3	Thyroid dysfunction	3	Discontinued	Permanently interrupted
3	Liver dysfunction	1	Thyroid dysfunction	1	Continued	NA
4	Diarrhea	2	Anorexia	1	Discontinued	Permanently interrupted

IrAE, immune-related adverse event; CTCAE, Common Terminology Criteria for Adverse Events; ICI, immune checkpoint inhibitor; NA, not applicable.